Communiqués Elicio Therapeutics, Inc.

Actions

ELTX

US28657F1030

Recherche biotechnologique et médicale

Cours en clôture Nasdaq 12/08/2026			Varia. 5j.	Varia. 1 janv.
3,060 ^USD	+0,99%		-4,08%	-61,56%

10/08	Elicio Therapeutics annonce le lancement d'une étude de phase 1 à l'initiative de l'investigateur sur l'ELI-002 7P en traitement néoadjuvant du carcinome canalaire pancréatique	CI
06/07	Elicio Therapeutics clôture une offre directe enregistrée de 15 millions de dollars	MT

Communiqués

10/08	Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma	GL
10/08	Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma	AQ
06/07	Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering	GL
02/07	Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering	GL
29/06	Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes	GL
17/06	Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer	GL
17/06	Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer	AQ
15/06	Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer	GL
15/06	Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer	AQ
01/06	Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology	GL
18/05	MIT: Big strides in cancer detection and treatment from the tiniest technologies	AQ
11/05	Elicio Therapeutics: Q1 Earnings Snapshot	AQ
11/05	Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates	GL
30/04	Elicio Therapeutics to Present at the Bank of America Healthcare Conference	GL
16/04	Elicio Therapeutics Reports Inducement Grants	GL
17/03	Elicio Therapeutics Reports Inducement Grants	GL
17/03	Elicio Therapeutics Reports Inducement Grants	AQ
12/03	Elicio Therapeutics: Q4 Earnings Snapshot	AQ
12/03	Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates	GL
25/02	Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference	GL
18/02	Elicio Therapeutics Reports Inducement Grants	GL
16/01	Elicio Therapeutics Reports Inducement Grants	GL
16/12	Elicio Therapeutics Reports Inducement Grants	GL
16/12	Elicio Therapeutics Reports Inducement Grants	AQ
11/12	Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial	GL